Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External + Endocavitary Brachytherapy + Concurrent Chemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

Next Previous
X
Search
Trial Profile

Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External + Endocavitary Brachytherapy + Concurrent Chemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CIGB 300 (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Elea

    • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 11 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top